Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 14/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 4/20 | 0.76 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13856184 | 0.86 | MYC (1.00) | MYCNR4A1NOTUMTDP1ALDH1A1 | |
| SCHEMBL17177037 | 0.82 | MYC (0.72) | MYCNR4A1PTPN1CTSB | |
| SCHEMBL15668582 | 0.81 | MYC (1.00) | MYCNR4A1 | |
| SCHEMBL15668778 | 0.79 | MYC (0.68) | MYCNR4A1ALDH1A1PTPN1CTSB | |
| SCHEMBL15668517 | 0.79 | MYC (0.76) | MYCNR4A1PTPN1CTSB | |
| SCHEMBL17172475 | 0.79 | MYC (0.75) | MYCTSHRSMN1; SMN2 | |
| SCHEMBL20861834 | 0.77 | MYC (0.79) | MYCNR4A1 | |
| SCHEMBL15714410 | 0.77 | MYC (0.64) | MYCNR4A1NOTUMPTPN1CTSB | |
| SCHEMBL15668668 | 0.77 | MYC (0.64) | MYCNR4A1PTPN1CTSB | |
| SCHEMBL15714460 | 0.76 | MYC (0.62) | MYCNR4A1PTPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917203-B1 | METHOD FOR IDENTIFYING MYC INHIBITORS | DANA FARBER CANCER INST INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2014071247-A1 | PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MYC 190/4885NR4A1 3756/4885NOTUM 3071/4885 |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | MCL1, BCL2, BCL2L1 | MYC 43/4885NR4A1 3528/4885NOTUM 4838/4885 |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | MCL1, BCL2, BCL2L1 | MYC 43/4885NR4A1 3528/4885NOTUM 4838/4885 |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | MCL1, BCL2, BCL2L1 | MYC 43/4885NR4A1 3528/4885NOTUM 4838/4885 |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | MYC, MYCBP, YAP1 | MYC 1/4885NR4A1 3212/4885NOTUM 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.